|Type||Antibiotics, protease, tyrosine kinase inhibitor|
|Keywords||COVID-19, HIV, antiviral, AIDS, SARS-CoV-2|
|Related products||Piperaquine, Chloroquine Diphosphate, Artemisinin, Acrichin Dihydrochloride|
|CAS Registry Number||155213-67-5|
|Molecular Weight||720.946 g/mol|
|Shelf life||2 years|
|Functions||Antiviral, therapy for HIV-1, potential inhibitor of COVID-19|
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. The mechanism of action of the anti-HIV drug lopinavir and ritonavir is to block the enzymes required for virus replication. Lopinavir/ritonavir have been shown to reduce coronavirus levels that cause SARS and MERS in animal studies.
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infected patients (adults and children of 2 years of age and older).
- L. Morissette; S. Soukasene; D. Levinson; M. J. Cima; O. Almarsson (2003). “Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization”
- Hsieh, Yi-Ling; Ilevbare, Grace A.; Van Eerdenbrugh, Bernard; Box, Karl J.; Sanchez-Felix, Manuel Vincente; Taylor, Lynne S. (2012-05-12). “pH-Induced Precipitation Behavior of Weakly Basic Compounds: Determination of Extent and Duration of Supersaturation Using Potentiometric Titration and Correlation to Solid State Properties”. Pharmaceutical Research. 29 (10): 2738–2753.
- Nieminen, Tuija H.; Hagelberg, Nora M.; Saari, Teijo I.; Neuvonen, Mikko; Neuvonen, Pertti J.; Laine, Kari; Olkkola, Klaus T. (2010). “Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir”. European Journal of Clinical Pharmacology. 66 (10): 977–985.